Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

New consortium EUbOPEN will provide tools to unlock disease biolog

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Oncology & Cancer Immunology

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Boehringer Ingelheim Acquires AMAL Therapeutics

Oncology & Cancer Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Medical Affairs & Scientific Comms. | Boehringer Ingelheim US

Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Boehringer’s unique approach to innovation

Boehringer’s unique approach to driving patient-centric innovation

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Sunshine Act Compliance

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Work Care Consortium | COVID-19 | Boehringer Ingelheim US

Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Mental Health disorders

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

New consortium EUbOPEN will provide tools to unlock disease biolog

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Oncology & Cancer Immunology

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Boehringer Ingelheim Acquires AMAL Therapeutics

Oncology & Cancer Immunology

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Medical Affairs & Scientific Comms. | Boehringer Ingelheim US

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Boehringer’s unique approach to innovation

Ridgefield, CT | BI Facilities

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Sunshine Act Compliance

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Work Care Consortium | COVID-19 | Boehringer Ingelheim US

Why cancer care is personal for us

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Mental Health disorders